Pluri (NASDAQ:PLUR) Stock Price Up 1.1% – Should You Buy?

Pluri Inc. (NASDAQ:PLUR) shares shot up 1.1% on Monday . The company traded as high as $1.8466 and last traded at $1.84. Approximately 14,944 shares changed hands during mid-day trading, a decline of 49% from the average session volume of 29,346 shares. The stock had previously closed at $1.82.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 23rd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pluri currently has a consensus rating of “Sell”.

Pluri Stock Up 1.1%

The stock has a market capitalization of $19.85 million, a P/E ratio of -0.41 and a beta of 0.67. The firm’s 50-day simple moving average is $1.98 and its 200 day simple moving average is $2.84.

Pluri (NASDAQ:PLUR) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.11. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.66 million.

Institutional Trading of Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC purchased a new position in Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri as of its most recent filing with the Securities & Exchange Commission. 16.59% of the stock is owned by institutional investors and hedge funds.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.